Helping Our Partners Deliver for Patients.

At WuXi AppTec, we operate with a clear vision: to ensure that every drug can be made, and every disease can be treated.

• We base our work on our core values of integrity and dedication.

• We prioritize customers, strive for excellence, achieve results, collaborate, and embrace change and innovation.

• We have over two decades of excellence in corporate governance and security.

• We adhere strictly to all U.S. laws and regulatory standards.

The Facts

Get the facts as we advise U.S. policymakers on pending legislation that would impact our customers’ ability to innovate and provide patient access to life-saving treatments.

News & Letters

• December 7, 2024 – Endpoints: Biosecure bill is left out of end-of-year defense package, dealing blow to chances

• August 28, 2024 – Boston Business Journal article

• June 11, 2024 – C&EN: Industry braces for Biosecure Act Impact

• May 11, 2024 – BioCentury: How WuXi AppTec is battling the Biosecure Act

• April 18, 2024 – The Economist: America's moves against Chinese biotech will hurt patients at home

• April 15, 2024 – The New York Times: Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs

• March 12, 2024 – Letter to Biotechnology Innovation Organization (BIO) CEO John Crowley Ending WuXi AppTec’s Membership

• February 2, 2024 – An Open Letter to our Customers from WuXi AppTec Leadership